Evolus Inc (EOLS) reaffirmed full-year revenue guidance of $330 million to $337 million while trimming operating expense outlook and advancing its injectable pipeline toward three launches by 2030.
The FDA has warned Evolus that an Instagram post for Jeuveau is false or misleading and misbrands the drug.
The FDA objected to claims suggesting Jeuveau could make frown lines gone, deliver complete results, and begin working within two days.
On August 5, Evolus (NASDAQ:EOLS) reported second-quarter 2026 results that showed the company finally translating years of growth into the bottom line. Global net revenue reached $84.1 million, up 21% over the prior year, and the company followed that up by raising its full-year 2026 outlook. The quarter also marked the third straight period of […]
The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
This is the newest page. Registered accounts read further back.